Recent news on Vidaza

Pharmion Corporation to Present at Upcoming Conferences  -  May 24, 2007
PharmaLive.com (press release),Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent.

Pharmion Corporation Reports Net Sales of $62.7 Million for Q1 2007  -  Apr 25, 2007
PR Newswire (press release),Worldwide sales of Vidaza(R) (azacitidine for injection) totaled $37.7 million in the first quarter of 2007, compared to $32.9 million in the same quarter

Pharmion Corporation Reports Net Sales of $62.7 Million for Q1 2007  -  26 Apr 2007
PR Newswire (press release),Worldwide sales of Vidaza(R) (azacitidine for injection) totaled $37.7 million in the first quarter of 2007, compared to $32.9 million in the same quarter

Oral Azacitidine Advances to Multi-Center, Multi-Cycle, Dose ...  -  Apr 23, 2007
PharmaLive.com (press release),In May 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza,

Pharmion Corporation to Present at Morgan Stanley Global ...  -  Apr 25, 2007
PharmaLive.com (press release),Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent.

Pharmion Corporation to Announce First Quarter 2007 Financial Results  -  Apr 18, 2007
PR-Inside.com (Pressemitteilung),Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent.

Analysis: Surge forecast for Pharmion drug  -  Mar 30, 2007
Science Daily (press release)He noted that the stock is vastly undervalued given its potential, with the anticipated increased use of Thalidomide and the European approvals of Vidaza

MethylGene Presents Clincal Biomarker Data for MGCD0103 at AACR ...  -  Apr 17, 2007
Web Services Journal,...treated with MGCD0103 alone or in combination with Vidaza®. There appeared to be a correlation between induction of IL-6 and clinical responsiveness.

MethylGene to Present at BioFinance 2007  -  Apr 23, 2007
Genetic Engineering News (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R) and Gemzar(R).

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor ...  -  Apr 19, 2007
PR Newswire (press release),This addresses an issue with re-activation of silenced tumor suppressor genes by 5-Azacytidine (5-AzaC or Vidaza) and its congener 5-aza- deoxycydinite

Pharmion sales off in 2006  -  Mar 15, 2007
Denver Business Journal,Pharmion has two drugs on the market -- Vidaza and Thalidomide Pharmion, both of which are used to treat cancers -- and another four in the pipeline.

Pharmion: Mixed Signals Prompt Caution on 2007 Outlook  -  Mar 13, 2007
Seeking Alpha,In addition the sales of Vidaza have flattened out as shown in Q4 results published in February. We believe this trend will continue in to 2007.

Pharmion Corporation Announces 2006 Operating Results  -  Feb 26, 2007
Drug Newswire (press release),Sales of Vidaza(R) (azacitidine for injection) totaled $142.2 million for 2006, compared to $125.6 million for 2005. Named patient and compassionate use

Myelodysplastic Syndromes  -  Mar 7, 2007
Cancer Focus,They suggested Vidaza." Ok, Vidaza is a typical approach for MDS, it is a drug which attempts to reawaken dormant genes that might still function.

Pharmion Corporation to Present At Cowen and Company 27th Annual ...  -  Mar 8, 2007
Primenewswire (press release),Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(r), a DNA demethylating agent.

MethylGene Reports Year-End 2006 Financial Results  -  Mar 8, 2007
Genetic Engineering News (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R) and Gemzar(R).

MethylGene Reports Year-End 2006 Financial Results  -  Mar 8, 2007
CCNMatthews (press release),Society of Hematology (ASH) annual meeting for the Phase I/II trial of MGCD0103 in combination with Vidaza ® (Trial 005) in patients with MDS or AML.

NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines  -  Feb 26, 2007
Business Wire (press release),The panel also added single agents azacytidine (Vidaza®, Pharmion) and decitabine (Dacogen™, MGI Pharma) to the guidelines as primary treatment for patients

NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines  -  Feb 26, 2007
Genetic Engineering News (press release),The panel also added single agents azacytidine (Vidaza(R), Pharmion) and decitabine (Dacogen(TM), MGI Pharma) to the guidelines as primary treatment for

Pharmion Corporation Announces 2006 Operating Results  -  Feb 21, 2007
Earthtimes.orgSales of Vidaza(R) (azacitidine for injection) totaled $142.2 million for 2006, compared to $125.6 million for 2005. Named patient and compassionate use

Investigational New Drug Accepted for Oral Formulation of Vidaza®  -  Feb 7, 2007
Cancer Consultants (press release),The United States Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application for an oral formulation of Vidaza

Pharmion: FDA approves IV administration for Vidaza  -  Jan 31, 2007
Pharmaceutical Business ReviewPharmion's Vidaza has received FDA approval to add intravenous use as a new route of administration to its label. The drug, which is used to treat

Pharmion Corporation Announces FDA Approval of Vidaza NDA ...  -  Jan 30, 2007
PipelineReview.com (press release),With this approval, Vidaza may now be administered intravenously over a period of 10 to 40 minutes in a clinic or hospital setting.

Pharmion Corporation Announces FDA Approval of Vidaza NDA ...  -  Jan 29, 2007
PR Newswire (press release),Vidaza Only Approved DNA Demethylation Agent With Labeled IV Administration of Less Than One Hour BOULDER, Colo., Jan. 29 /PRNewswire-FirstCall/ -- Pharmion

Intravenous Formulation of Vidaza® Approved  -  Feb 1, 2007
Cancer Consultants (press release),The United States Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Pharmion’s Vidaza (azacitidine) in the treatment of

UPDATE 1-Pharmion says FDA OKs intravenous use of Vidaza  -  Jan 29, 2007
ReutersThe injectable drug, Vidaza, can now be administered over a period of 10 to 40 minutes in a clinic or hospital setting, the biotechnology company said.

FDA accepts Pharmion's IND for oral Vidaza  -  Jan 31, 2007
United Press International31 (UPI) -- Pharmion said Wednesday the US Food and Drug Administration accepted its investigational new drug application for an oral formulation of Vidaza.

Pharmion's Vidaza OK'd for IV use  -  Jan 29, 2007
United Press InternationalThe company said the FDA action means Vidaza can now be administered intravenously over a period of 10 to 40 minutes in a clinic or hospital.

Pharmion's New Vidaza Approval Sends Stock Soaring  -  Jan 30, 2007
Seeking Alpha,In May 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes [MDS] a serious cancer like blood

New Administration Route Approved for Vidaza  -  Jan 31, 2007
Facts and Comparisons,The FDA has approved Pharmion Corporation’s SNDA for Vidaza (azacitidine) injection for the addition of intravenous use as a route of administration.

Pharmion Gets FDA OK for Vidaza Study  -  Jan 31, 2007
Forbes,Pharmion Corp. said Wednesday the Food and Drug Administration approved its application to test an oral formulation of its injectible drug Vidaza.

Pharmion's Vidaza Gets Another Approval  -  Jan 29, 2007
Forbes,Pharmion Corp. said Monday the Food and Drug Administration approved an additional use for its blood and bone marrow disorders drug Vidaza.

Pharmion says FDA OKs new IV use of Vidaza  -  Jan 29, 2007
ReutersPharmion said its injectable drug, Vidaza, can now be administered over a period of 10 to 40 minutes in a clinic or hospital setting.

Market Report -- In Play (PHRM)  -  Feb 22, 2007
MSN MoneyPHRM reports 4Q06 Vidaza sales of $36.6 mln vs. $35.22 mln street expectation. Co issues in-line guidance for FY07, sees FY07 revs of $240-250 vs.

Pharmion Expects Revenue Growth in 2007  -  Feb 21, 2007
Forbes,Also, the company said it plans to ask European regulators to approve its Vidaza drug to treat high-risk myelodysplastic syndromes or blood and bone marrow

Pharmion Announces FDA Acceptance of IND for Oral Azacitidine  -  Feb 1, 2007
PipelineReview.com (press release),Pharmion currently markets the parenteral formulation of azacitidine, known as Vidaza(R) (azacitidine for injection) for the treatment of patients with

Pharmion Announces FDA Acceptance of IND for Oral Azacitidine  -  Jan 31, 2007
Yahoo! News (press release)Pharmion currently markets the parenteral formulation of azacitidine, known as Vidaza® (azacitidine for injection) for the treatment of patients with

Market Report -- In Play (PHRM)  -  Jan 29, 2007
MSN MoneyPharmion announces FDA approval of Vidaza NDA supplement for IV administration Co announces it has received approval from the FDA for its new drug

Buyout War Helped Real Estate Top Sectors In Jan.  -  Feb 5, 2007
Investor's Business Daily (subscription)Its drug Vidaza is used to treat certain high-risk bone marrow disorders. "Some investors thought competitors like MGI Pharma (MOGN) would crush Vidaza,"

FDA OKs Pharmion drug delivery  -  Jan 30, 2007
Bizjournals.com,Pharmion Corp. said Monday the US Food and Drug Administration has approved a new way to administer its drug Vidaza. The Boulder company (NASDAQ: PHRM) said

Sysco Among Wall Street's Big Movers  -  Jan 29, 2007
Forbes,The drug maker won Food and Drug Administration approval for an additional use for Vidaza, a drug to treat blood and bone marrow disorders.

Liberty Media leads increase in state stocks  -  Jan 30, 2007
Rocky Mountain News,The drugmaker said the Food and Drug Administration cleared its Vidaza treatment for some intravenous use. Denver-based Chipotle Mexican Grill,

Satraplatin Shown to Significantly Reduce Risk of Disease ...  -  Feb 23, 2007
American Digital Networks (press release),Pharmion has a number of products on the market including the world's first approved epigenetic cancer drug, Vidaza(R), a DNA demethylating agent.

Reminder: Pharmion Corporation to Announce Fourth Quarter and Year ...  -  Feb 21, 2007
PharmaLive.com (press release),Pharmion has a number of products on the market including the world's first approved epigenetic cancer drug, Vidaza(R), a DNA demethylating agent.

Pharmion Corporation to Announce Fourth Quarter and Year-End 2006 ...  -  Feb 15, 2007
Yahoo! News (press release)Pharmion has a number of products on the market including the world's first approved epigenetic cancer drug, Vidaza®, a DNA demethylating agent.

MethylGene announces C$20 million bought deal financing  -  Feb 13, 2007
CNW Telbec (Communiqués de presse),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R) and Gemzar(R).

Investor Biotech Primer  -  Feb 8, 2007
TheStreet.comPharmion (PHRM - Cramer's Take - Stockpickr) announced last week that the FDA accepted the company's IND for an oral version of Vidaza, a treatment for

MethylGene to Present at the Annual BIO CEO & Investor Conference  -  Feb 6, 2007
CCNMatthews (press release),...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza ® and Gemzar ® .

MethylGene to Present at the Annual BIO CEO & Investor Conference  -  Feb 6, 2007
Market Wire (press release)...trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza® and Gemzar®.

Any life left in earnings party?  -  Jan 29, 2007
Denver Post,Pharmion also announced plans to file European marketing applications for its Thalidomide, Satraplatin and Vidaza drugs, which treat myeloma,

Mylotarg® and Vidaza® Effective for Elderly Patients with AML or MDS  -  Jan 5, 2007
Cancer Consultants (press release),Researchers from Loyola University have reported that the combination of Mylotarg® (gemtuzumab ozogamicin) and Vidaza® (azacitidine) produces a high rate of

New Data Validate Vidaza(R) Response Rates In MDS And Report ...  -  Dec 26, 2006
Medical News Today (press release),In this study of 78 patients evaluable for response after four cycles of Vidaza, overall response was 74 percent, including 14 percent complete responders,

Pharmion Provides Strategic Objectives and Financial Guidance for ...  -  Jan 9, 2007
PR Newswire (press release),EU marketing authorization applications planned for Thalidomide Pharmion, Satraplatin and Vidaza * Registration studies expected to initiate for Amrubicin

CEO: Pharmion Has Evolved, Could 'Transform' During '07  -  Jan 10, 2007
BioWorld Online,Among the likely milestones due this year is FDA approval of an intravenous formulation of Vidaza, for which the original PDUFA came and went this fall.

Pharmion Provides Strategic Objectives and Financial Guidance for ...  -  Jan 9, 2007
Genetic Engineering News (press release),These include the supplemental NDA currently under review by the US FDA to add IV administration for Vidaza, and the MAA to be filed in early 2007 with the

Pharmion Provides Strategic Objectives and Financial Guidance for ...  -  Jan 9, 2007
MSN MoneyOverall survival data from pivotal studies expected for Vidaza and Satraplatin * Company anticipates net sales of approximately $239 million for 2006,

Pharmion Sales Outlook Above Street  -  Jan 9, 2007
Houston Chronicle,The company also expects the Food and Drug Administration to expand its approval of Vidaza to allow an intravenous form of the drug during the year.

UPDATE 1-Pharmion raises 2006 net sales outlook, sets 2007 view  -  Jan 9, 2007
ReutersVidaza, which is already sold in the United States, treats a group of blood disorders called myelodysplastic syndromes that can lead to leukemia.

Market Report -- In Play (PHRM)  -  Jan 9, 2007
MSN MoneyCo also notes that EU marketing authorization applications are planned for Thalidomide Pharmion, Satraplatin and Vidaza. Co states that registration studies

Pharmion Corporation to Present at 25th Annual JPMorgan Healthcare ...  -  Jan 4, 2007
PharmaLive.com (press release),Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent.

New Data Validate Vidaza(R) Response Rates In MDS And Report ...  -  26 Dec 2006
Medical News Today (press release),In this study of 78 patients evaluable for response after four cycles of Vidaza, overall response was 74 percent, including 14 percent complete responders,

New Data Demonstrate Clinical Activity of Vidaza in Combination ...  -  Dec 12, 2006
PharmaLive.com (press release),The relative contribution of MS-275 is currently under examination in an ECOG study randomizing patients to the Vidaza/MS-275 combination versus the

New Data Demonstrate Clinical Activity of Vidaza(R) in Combination ...  -  Dec 11, 2006
PR Newswire (press release),Significant Clinical Activity of the Combination of Vidaza, Valproic Acid and All-Trans Retinoic Acid (ATRA) in Leukemia (Abstract 160) Andres Soriano, MD,

New Data Demonstrate Clinical Activity of Vidaza(R) in Combination ...  -  Dec 11, 2006
PR Newswire UK (press release),Pharmion Corporation (Nasdaq: PHRM) announced new data presented today from three studies of Vidaza(R) (azacitidine for injectable suspension) in

New Data Demonstrate Clinical Activity of Vidaza(R) in Combination ...  -  Dec 11, 2006
Earthtimes.org11 -- Pharmion Corporation announced new data presented today from three studies of Vidaza(R) (azacitidine for injectable suspension) in combination with

New Data Validate Vidaza(R) Response Rates in MDS and Report ...  -  Dec 11, 2006
PR Newswire (press release),Data on Vidaza Use in High Risk MDS and AML Post-MDS Demonstrate Response Rates of 74 Percent (Abstract 2664, Poster 842-II) Claire Fabre, MD, of the Groupe

New data on Vidaza in MDS and AML  -  Dec 11, 2006
Pharmaceutical Business ReviewPharmion Corporation has presented new data on Vidaza (azacitidine for injectable suspension) as single-agent therapy for the treatment of myelodysplastic

Pharmion Says New Data Demonstrate Clinical Activity Of Vidaza ...  -  Dec 12, 2006
Trading Markets,...(PHRM | charts | news | PowerRating) revealed new data presented from three studies of Vidaza in combination with several histone deacetylase inhibitors,

Clinical Data on Pharmion's Epigenetic Therapies in Higher-Risk ...  -  Dec 7, 2006
Drug Newswire (press release),In May 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza,

Clinical Data on Pharmion's Epigenetic Therapies in Higher-Risk ...  -  Dec 7, 2006
PR Newswire (press release),27 Vidaza(R) (azacitidine for injectable suspension) abstracts at ASH, including two oral and 16 poster presentations * Data on Vidaza as monotherapy and in

Clinical Data on Pharmion's Epigenetic Therapies in Higher-Risk ...  -  Dec 7, 2006
Earthtimes.org7 -- Pharmion Corporation reported today that data from several studies of its epigenetic therapies, Vidaza and MGCD0103, will be presented at the American

Pharmion Corp. Is Climbing On Upgrade News  -  Dec 11, 2006
Trading Markets,...(PHRM | charts | news | PowerRating) on Monday revealed the data on its drug candidate Vidaza for the treatment of myelodysplastic syndromes and acute

Positive Data Reported at ASH Annual Meeting for MethylGene's ...  -  Dec 11, 2006
Genetic Engineering News (press release),Azacitidine (Vidaza(R)) is administered at its approved dose and schedule of 75mg/m2 SC daily x 7 every 28 days. Seven out of 23 evaluable patients,

Positive Data Reported at ASH Annual Meeting for MethylGene's ...  -  Dec 11, 2006
Market Wire (press release)The combination of azacitidine (Vidaza®) with MGCD0103 has encouraging safety, PK and clinical activity profiles and appears to be well-tolerated in

Canaccord Adams Starts Pharmion (PHRM) at Buy  -  Dec 8, 2006
StreetInsider.com (subscription),Analyst David Bouchey said, "Concerns that competition could erode sales and cap the growth for Vidaza and Thalidomide have depressed the share price.

Market Report -- In Play (PHRM)  -  Dec 12, 2006
MSN MoneyPharmion says new data demonstrate clinical activity of Vidaza in combination with HDAC inhibitors in treatment of higher-risk MDS and AML Co announces new

Pharmion upgraded to "neutral weight"  -  Dec 12, 2006
newratings.comIn a research note published yesterday, the analyst mentions that the outlook for Vidaza's competitive position in the MDS market has improved.

(PRN) - Genesco Announces Agreement to Acquire Hat Shack, Inc. ... [+]  -  Dec 11, 2006
Bolsamania.com,...(PRN) - New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML ... [+]. (PRN) - Calamos Asset Management, Inc. Announces Assets Under

Sección internacional  -  Dec 11, 2006
Bolsamania.com,...(PRN) - New Data Demonstrate Clinical Activity of Vidaza(R) in Combination With HDAC Inhibitors in the Treatment of Higher-Risk MDS and AML ... [+]

Friedman Billings Adds Pharmion (PHRM) a biotech Top Pick  -  Nov 29, 2006
StreetInsider.com (subscription),Drivers for outperformance include: further evidence from monthly data that Vidaza can survive - and even grow " with Dacogen now on the market,

Pharmion Acquires Cabrellis Pharmaceuticals  -  Dec 4, 2006
Pharmaceutical Online (press release),Complements Pharmion's epigenetic platform -- Current research indicates that by relaxing chromatin conformation, Vidaza and MGCD0103 increase access of

Combination of Azacitidine and Experimental MS-275 Produces ...  -  Dec 13, 2006
DG NewsORLANDO, FL -- December 13, 2006 -- The combination of 5-azacitidine (Vidaza) in combination with the experimental histone deacetylase inhibitor, MS-275,

New Data Show That the Addition of Thalidomide to Myeloma ...  -  Dec 13, 2006
PharmaLive.com (press release),Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent.

New drugs attack blood diseases  -  Dec 12, 2006
Monsters and Critics.com,Researchers looked at the use of 5-axacitidine (Vidaza) in combination with a experimental drug, MS-275, a histone deacetylase inhibitor -- a drug that

The Navicor Group Honored at 2006 Rx Club Awards  -  Dec 12, 2006
PharmaLive.com (press release),3-D mailer category; * "2005 ASH experience" for VIDAZA; in the posters/display/special projects/trade shows: premiums/promotions category;

(PRN) - Calamos Asset Management, Inc. Announces Assets Under ...  -  Dec 11, 2006
Bolsamania.com,...(PRN) - New Data Validate Vidaza(R) Response Rates in MDS and Report Results in AML ... [+]. (PRN) - Holly Corporation Announces Regular Quarterly Cash

MethylGene Initiates Phase II Clinical Trial with its Proprietary ...  -  Dec 7, 2006
CCNMatthews (press release),...a Phase I/II combination trial with the demethylating agent Vidaza ® (azacitidine for injectable suspension, marketed by Pharmion) in patients with

Dec 07, 2006 MONTREAL, QUEBEC MARKET WIRE  -  Dec 7, 2006
Genetic Engineering News (press release),...a Phase I/II combination trial with the demethylating agent Vidaza(R) (azacitidine for injectable suspension, marketed by Pharmion) in patients with

MethylGene Initiates Phase II Clinical Trial with its Proprietary ...  -  Dec 7, 2006
Market Wire (press release)...a Phase I/II combination trial with the demethylating agent Vidaza® (azacitidine for injectable suspension, marketed by Pharmion) in patients with

MethylGene Announces Two Poster Presentations Highlighting its ...  -  Dec 4, 2006
Market Wire (press release)At the conference, data from two MGCD0103 clinical trials will be presented: Trial 005, a Phase I/II combination trial with Vidaza® in patients with acute

131 Abstracts Evaluating Celgene Products to Be Presented at the ...  -  Dec 7, 2006
PR Newswire (press release),...related genes in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (AML) patients with resistance to low dose Vidaza and thalidomide;

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional